Amgen Pauses or Discontinues Several Therapeutics in Oncology Pipeline
Amgen released its financial results for the fourth quarter and full year 2020. Among the key results, Amgen disclosed that […]
Amgen Announces Positive Interim Data from CodeBreaK 100 Trial of Sotorasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
Amgen announced results from the Phase 2 cohort of the CodeBreaK 100 study evaluating sotorasib (AMG 510) in 126 patients […]
Dr. Ian Smith And Stuart Young Talk About Lessons From Covid-19: Strategy For Recruiting Patients
An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera […]
NIH Awards $4m for Memorial Sloan Kettering & City College NY to Train AI to Detect Breast Cancer Tumors in At-Risk Women
The National Institutes of Health awarded $4 million to Memorial Sloan Kettering Cancer Center (MSKCC) and the City College of […]
FDA Grants Orphan Drug Designation to BCMA-targeting Specific T Cell Activating Recombinant Protein (HPN217) for Patients with Multiple Myeloma
The U.S. Food and Drug Administration decided to open the Orphan Drug Designation (ODD) to an investigational drug for the […]
Regional Oncology Network Joins OneOncology Platform and the ‘OneR’ Clinical Trials Network
A group of 37 medical and radiation oncologists, along with a robust staff of cancer care providers, led by Drs. […]
China’s Regulator Accepts Amgen’s Sotorasib for Breakthrough Therapy Designation as a First Milestone
Amgen, a leading global biotech company based in Southern California reported a first—the first time it has successfully achieved Breakthrough […]
St. Baldrick’s Foundation and TeamConnor Childhood Cancer Foundation Partner to Back the Work of Dr. Erica Braverman at Children’s Hospital of Pittsburgh
A prominent non-government funder of childhood research grants, the St. Baldrick’s Foundation, formalized a partnership with the Dallas, Texas, based […]
AstraZeneca’s Calquence Meets Primary Efficacy Endpoint in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
AstraZeneca reported positive results from the phase 3 ELEVATE-RR trial, which evaluated AstraZeneca’s Calquence (acalabrutinib) versus ibrutinib in adults with previously treated, […]
BeiGene’s Tislelizumab Meets Endpoints in Phase 3 Trial for Esophageal Cancer
BeiGene reported positive results from the global Phase RATIONALE 302 trial evaluating its anti-PD-1 antibody tislelizumab versus investigator’s choice chemotherapy […]
